Licence agreement
Gene therapy specialist Oxford BioMedica plc said it has expanded an existing licence agreement for its LentiVector gene delivery technology with a major (unnamed) multinational pharmaceutical company. The amendment broadens the agreement from an annual license for use for research activities in the US to a worldwide perpetual licence.
Under the terms of the amended agreement, Oxford BioMedica will receive a one-time undisclosed payment from the licensee, but no further financial details were not disclosed.
LentiVector, can be used to deliver genes to a wide range of cell and tissue types and has applications gene therapy and as a tool for drug discovery.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
